Scholar Rock will use the proceeds from the Kraft Group-backed round to advance its lead spinal muscular atrophy drug candidate into clinical development.
Scholar Rock, a US-based spinal muscular atrophy (SMA) drug developer, completed a $47m series C round yesterday that included diversified conglomerate Kraft Group.
Hedge fund Redmile Group led the round, which also featured financial services group Fidelity Management and Research, Polaris Partners, Arch Venture Partners, EcoR1 Capital, Cormorant Asset Management and Scholar Rock founder Timothy Springer.
The series C funds will support the progress of Scholar Rock’s lead drug candidate, SRK-015, a treatment for SMA and other neuromuscular disorders, into…
